MeiraGTx Holdings plc Payments to Acquire Long-term Investments
MeiraGTx Holdings plc (MGTX) reported Payments to Acquire Long-term Investments of $6.50 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLongtermInvestments · last filed 2023-03-14
- MeiraGTx Holdings plc payments to acquire long-term investments for the quarter ending 2021-12-31 was $1.00M.
- MeiraGTx Holdings plc payments to acquire long-term investments for the quarter ending 2021-09-30 was $0.00.
- MeiraGTx Holdings plc payments to acquire long-term investments for the quarter ending 2021-06-30 was $0.00.
- MeiraGTx Holdings plc payments to acquire long-term investments for the quarter ending 2021-03-31 was $5.50M.
- MeiraGTx Holdings plc payments to acquire long-term investments for fiscal 2021 was $6.50M.
| Period end | Payments to Acquire Long-term Investments 3 month | Payments to Acquire Long-term Investments 6 month | Payments to Acquire Long-term Investments 9 month | Payments to Acquire Long-term Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $1.00M derived: sum of 2 quarters · filed 2023-03-14 | $1.00M derived: sum of 3 quarters · filed 2023-03-14 | $6.50M 10-K · filed 2023-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $5.50M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $5.50M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $5.50M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |